Literature DB >> 8054006

Role of recombinant interleukin-2 in combination with interferon-alfa and chemotherapy in the treatment of advanced melanoma.

S S Legha1, A C Buzaid.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8054006

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


× No keyword cloud information.
  8 in total

Review 1.  Liquid Biopsies for Assessing Metastatic Melanoma Progression.

Authors:  Kelly Huynh; Dave S B Hoon
Journal:  Crit Rev Oncog       Date:  2016

2.  Circulating DNA microsatellites: molecular determinants of response to biochemotherapy in patients with metastatic melanoma.

Authors:  Bret Taback; Steven J O'Day; Peter D Boasberg; Sherry Shu; Patricia Fournier; Robert Elashoff; He-Jing Wang; Dave S B Hoon
Journal:  J Natl Cancer Inst       Date:  2004-01-21       Impact factor: 13.506

3.  Intermittent interferon and polychemotherapy in metastatic melanoma.

Authors:  M S Vuoristo; P Gröhn; P Kellokumpu-Lehtinen; E Kumpulainen; M Turunen; M Korpela; H Joensuu; K Tiusanen; A Nevantaus
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

Review 4.  Biological response modifiers in cancer.

Authors:  Purabi Reang; Madhur Gupta; Kamlesh Kohli
Journal:  MedGenMed       Date:  2006-11-14

5.  A phase II trial of piroxantrone in disseminated malignant melanoma. A Southwest Oncology Group study.

Authors:  J A Sosman; L E Flaherty; P Y Liu; W Fletcher; J A Thompson; A Hantel; V Sondak
Journal:  Invest New Drugs       Date:  1995       Impact factor: 3.850

6.  Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group.

Authors:  Michael B Atkins; Jessie Hsu; Sandra Lee; Gary I Cohen; Lawrence E Flaherty; Jeffrey A Sosman; Vernon K Sondak; John M Kirkwood
Journal:  J Clin Oncol       Date:  2008-11-10       Impact factor: 44.544

7.  Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma.

Authors:  S R Johnston; D O Constenla; J Moore; H Atkinson; R P A'Hern; G Dadian; P G Riches; M E Gore
Journal:  Br J Cancer       Date:  1998-04       Impact factor: 7.640

8.  Dose efficacy study of two schedules of high-dose bolus administration of interleukin 2 and interferon alpha in metastatic melanoma.

Authors:  W H Kruit; C J Punt; S H Goey; P H de Mulder; J W Gratama; A M Eggermont; R L Bolhuis; G Stoter
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.